DAFNA Capital Management »

Aprea Therapeutics shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of Aprea Therapeutics (APRE) shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in Aprea Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aprea Therapeutics held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aprea Therapeutics by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $558k 137k 4.07
2024-03-31 $918k 137k 6.69

More positions owned by DAFNA Capital Management

Spdr S&p Biotech Etf Etf (XBI)
Stereotaxis Com New (STXS)
Merus N V (MRUS)
Cytokinetics Com New (CYTK)
Revolution Medicines (RVMD)
Ideaya Biosciences (IDYA)
AtriCure (ATRC)
Ishares Nasdaq Biotech Indx Etf (IBB)
Syndax Pharmaceuticals (SNDX)
Blueprint Medicines (BPMC)
Ascendis Pharma A/s Sponsored Adr (ASND)
Xenon Pharmaceuticals (XENE)
Viking Therapeutics (VKTX)
Neurocrine Biosciences (NBIX)
Kalvista Pharmaceuticals (KALV)

View all positions for DAFNA Capital Management

Top funds holding Aprea Therapeutics

AIGH Capital Management
Sio Capital Management
Sphera Funds Management
Nantahala Capital Management
Altium Capital Management
DAFNA Capital Management
Exome Asset Management
Stonepine Capital Management
Vanguard Group
Geode Capital Management
Morgan Stanley
Dimensional Fund Advisors
HighTower Advisors
Susquehanna International
BlackRock

View all funds holding Aprea Therapeutics